Cargando...
p53-inducible ribonucleotide reductase (p53R2/RRM2B) is a DNA hypomethylation-independent decitabine gene target that correlates with clinical response in MDS/AML
While the therapeutic activity of the deoxycytidine analog decitabine is thought to reflect its ability to reactivate methylation-silenced genes, this agent is also known to trigger p53-dependent DNA damage responses. Here we report that p53-inducible ribonucleotide reductase (p53R2/RRM2B) is a robu...
Gardado en:
| Main Authors: | , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
2008
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2606040/ https://ncbi.nlm.nih.gov/pubmed/19010910 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-08-1860 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|